DESTINY-CRC02: Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer
An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.
Source: onclive.com
Kras Mutations News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kras Mutations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kras Mutations Today - Breaking & Trending Today
Personalized Medicine Coalition Report Review
The PMC released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022. The report summarizes the improved patient outcomes and urges policymakers to continue to support policies that encourage advancement.
Source: natlawreview.com